Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.78 |
| ▸ | ERBB2 | P04626 | 20/20 | 0.78 |
| ▸ | ERBB4 | Q15303 | 10/20 | 0.70 |
| ▸ | ERBB3 | P21860 | 9/20 | 0.70 |
| ▸ | LCK | P06239 | 1/20 | 0.63 |
| ▸ | LYN | P07948 | 1/20 | 0.63 |
| ▸ | MET | P08581 | 1/20 | 0.63 |
| ▸ | CSK | P41240 | 1/20 | 0.63 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748591 | 0.91 | EGFR (0.85) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL2749729 | 0.91 | EGFR (0.72) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL3129751 | 0.90 | EGFR (0.76) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL3507583 | 0.89 | EGFR (0.78) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL986142 | 0.88 | EGFR (1.00) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL3124458 | 0.84 | EGFR (0.88) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL14494932 | 0.84 | EGFR (0.76) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL13423929 | 0.83 | EGFR (0.61) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL2748279 | 0.83 | EGFR (0.77) | EGFRERBB2ERBB4ERBB3LCK | |
| SCHEMBL3509066 | 0.83 | EGFR (1.00) | EGFRERBB2ERBB4ERBB3LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216788-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216788-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216788-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| WO-2010036910-A1 | HEART PROTECTION BY ADMINISTERING AN AMP-ACTIVATED PROTEIN KINASE ACTIVATOR | OHTA YOSHIKAZU (JP) | 2010-04-01 | — | — | WO | disclosed |
| WO-2010036928-A1 | PREVENTION AND TREATMENT OF CANCER WITH LKB1 NON-EXPRESSION (DELETION OR MUTATION) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-01 | — | — | WO | disclosed |
| EP-1957495-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007064045-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007064045-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216788-A1 | FUSED HETEROCYCLIC COMPOUND | GRK6, FGFR1, PTK6 | EGFR 54/4885ERBB2 31/4885ERBB4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.